Previous 10 | Next 10 |
home / stock / msclf / msclf news
Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced to...
Elizabeth Williams, CPA, CA, joins as CFO, bringing extensive expertise leading corporate finance and strategy for public biotech companies listed on Nasdaq and TSX. Current CFO, Warren Whitehead, CPA, CMA, transitions to Head of Corporate Strategy to focus on strengthening and expanding colla...
2023-08-29 09:44:21 ET Satellos Bioscience press release ( OTC:MSCLF ): Q2 net loss was $4.1 million. Cash and cash equivalents of $48.7 million as at June 30, 2023. For further details see: Satellos Bioscience reports Q2 results
$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC") through Phase I clinical development in healthy human volunteers and Duchenne muscular dystrophy patients Toronto, Ontario--(Newsfile Corp. - August 29, 2023...
Company also recently received Rare Pediatric Disease Designation from the FDA for SAT-3153 for the treatment of pediatric patients with Duchenne Toronto, Ontario--(Newsfile Corp. - August 2, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a dru...
Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today the results of its annual ...
2023-06-07 07:23:14 ET Satellos Bioscience ( OTC:MSCLF ) on Wednesday notifies the appointment of Alan K. Jacobs, MD as Chief Medical Officer of the company, effective June 7, 2023. Dr. Jacobs, most recently served as Vice President, Clinical Development, Neuroscience fo...
Dr. Alan K. Jacobs joins Satellos as CMO on June 7th, 2023 Toronto, Ontario--(Newsfile Corp. - June 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle disea...
Toronto, Ontario--(Newsfile Corp. - June 1, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that its board of directors (...
2023-05-31 05:32:00 ET Satellos Bioscience press release ( OTC:MSCLF ): Q1 GAAP EPS of -C$0.04 in-line. Cash and cash equivalents of C$2.98M. For further details see: Satellos Bioscience GAAP EPS of -C$0.04 in-line
News, Short Squeeze, Breakout and More Instantly...
– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) ...
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to initiate a Phase 1 clinical trial in Q3 2024 Satellos Bios...
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company d...